Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00449501
Other study ID # D5896C00025
Secondary ID
Status Completed
Phase Phase 3
First received March 16, 2007
Last updated January 21, 2011
Start date March 2007
Est. completion date November 2007

Study information

Verified date January 2011
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily.


Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date November 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or Female, > 18 years of age

- Mild to moderate asthma requiring treatment with an inhaled corticosteroid

- Diagnosis of asthma for at least 6 months

Exclusion Criteria:

- Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)

- Subjects with severe asthma, as judged by investigator

- Any significant disease or disorder that may jeopardize a subject's safety

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Budesonide/formoterol pMDI

Budesonide HFA pMDI


Locations

Country Name City State
United States Research Site Akron Ohio
United States Research Site Anaheim California
United States Research Site Avon Indiana
United States Research Site Bay City Michigan
United States Research Site Bend Oregon
United States Research Site Bensalem Pennsylvania
United States Research Site Bismarck North Dakota
United States Research Site Boerne Texas
United States Research Site Brick New Jersey
United States Research Site Charleston South Carolina
United States Research Site Chesterfield Missouri
United States Research Site Dallas Texas
United States Research Site Denver Colorado
United States Research Site East Providence Rhode Island
United States Research Site El Paso Texas
United States Research Site Fargo North Dakota
United States Research Site Feasterville Pennsylvania
United States Research Site Gaffney South Carolina
United States Research Site Greer South Carolina
United States Research Site Iowa City Iowa
United States Research Site Kansas City Missouri
United States Research Site Lake Oswego Oregon
United States Research Site Little Rock Arkansas
United States Research Site Los Angeles California
United States Research Site Mandeville Louisiana
United States Research Site McCook Nebraska
United States Research Site Miami Florida
United States Research Site Muscle Shoals Alabama
United States Research Site North Syracuse New York
United States Research Site Oklahoma City Oklahoma
United States Research Site Palmdale California
United States Research Site Pittsburgh Pennsylvania
United States Research Site Princeton New Jersey
United States Research Site Provo Utah
United States Research Site Rapid City South Dakota
United States Research Site Rolling Hills Estates California
United States Research Site San Antonio Texas
United States Research Site Scottsbluff Nebraska
United States Research Site Shawnee Mission Kansas
United States Research Site Spokane Washington
United States Research Site Stamford Connecticut
United States Research Site Waco Texas
United States Research Site Watertown South Dakota
United States Research Site Wheat Ridge Colorado
United States Research Site Wheaton Maryland
United States Research Site Wilmington Delaware

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine whether subjects respond similarly to the Onset of Effect Questionnaire items 2 and 5 when administered post-dose versus pre-dose and does that difference favour a bronchodilator treatment group over a non-bronchodilator treatment group
Secondary To determine if there is an association between the immediate physiological response to medication and the responses to OEQ items 2 and 5 and to determine what subjects mean when they say they feel their asthma maintenance medication 'working right away
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device